Exercise Capacity, Pulmonary Function and Physical Activity Level in Patients Lung Cancer Undergoing Pneumonectomy
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04807153 |
|
Recruitment Status :
Recruiting
First Posted : March 19, 2021
Last Update Posted : March 30, 2021
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Pneumonectomy is a high-risk surgical procedure, causing impaired respiratory functions and exercise intolerance. It is associated with decreased physical activity, quality of life and increased fatigue.
The primary aim of the study is to compare the exercise capacity and respiratory functions of lung cancer patients undergoing pneumonectomy and healthy individuals. The secondary aim of the study is to compare peripheral and respiratory muscle strength, respiratory muscle endurance, physical activity level, shortness of breath, fatigue and quality of life of lung cancer patients undergoing pneumonectomy and healthy individuals.
| Condition or disease |
|---|
| Pneumonectomy; Status |
Pneumonectomy is a high risk surgical procedure compared to lobectomy, segmentectomy and non-anatomical resection. Pneumonectomy causes impairment of respiratory functions and exercise intolerance. Assessment of exercise capacity in pneumonectomy is prognostically important. Exercise intolerance can also occur with daily activities using the upper extremity. There is no study investigated upper extremity exercise capacity in this patient population. Postoperative pulmonary functions are determinant for early postoperative results as well as long-term postoperative quality of life. Therefore, it is necessary to evaluate respiratory functions in patients after surgery. Respiratory muscle functions are impaired due to changes in chest wall mechanics and incisions applied to respiratory muscles after surgery. There is no study investigated respiratory muscle endurance in this patient population.
Pneumonectomy is associated with decreased physical activity and quality of life. The number of studies investigating physical activity level in lung cancer patients undergoing pneumonectomy is limited. In this study, physical activity level will be evaluated by metabolic holter. Pneumonectomy has been shown as a predictor of deterioration in quality of life after surgery. In this study, the quality of life will be evaluated using a questionnaire specific to the disease. Fatigue is a common symptom in patients after lung cancer surgery. It negatively affects the patients quality of life and long-term prognosis.
Lung cancer patients undergoing pneumonectomy by the physicians of Gazi University Thoracic Surgery Department and healthy individuals will be included in this study. Patients and healthy individuals will be evaluated and the evaluation results will be compared. According to the sample size analysis 17 patients and 17 healthy individuals with similar demographic characteristics will be included the study. Patients and healthy individuals will be selected according to predetermined inclusion and exclusion criteria. The assessments will be completed in two days.
Functional exercise capacity (6 minutes walk test), upper extremity exercise capacity (6 minutes Pegboard and Ring Test), respiratory functions (spirometer), respiratory muscle strength (mouth pressure measurement), peripheral muscle strength (dynamometer), respiratory muscle endurance (incremental threshold loading test), physical activity level (multi-sensor activity monitor), quality of life (European Cancer Research and Treatment Organization Quality of Life Scale (EORTC QOL C-30)), fatigue (Fatigue Severity Scale) and shortness of breath (Modified Medical Research Council (MMRC)) will be evaluated.
| Study Type : | Observational |
| Estimated Enrollment : | 34 participants |
| Observational Model: | Case-Control |
| Time Perspective: | Cross-Sectional |
| Official Title: | Exercise Capacity, Pulmonary Function and Physical Activity Levels in Patients With Lung Cancer Undergoing Pneumonectomy |
| Actual Study Start Date : | March 15, 2021 |
| Estimated Primary Completion Date : | December 2021 |
| Estimated Study Completion Date : | December 2022 |
| Group/Cohort |
|---|
|
Patients
Functional exercise capacity (6 minutes walk test), upper extremity exercise capacity (6 minutes Pegboard and Ring Test), respiratory functions (spirometer), respiratory muscle strength (mouth pressure measurement), peripheral muscle strength (dynamometer), respiratory muscle endurance (incremental threshold loading test), physical activity level (multi-sensor activity monitor), quality of life (European Cancer Research and Treatment Organization Quality of Life Scale (EORTC QOL C-30)), fatigue (Fatigue Severity Scale) and shortness of breath (Modified Medical Research Council (MMRC)) will be evaluated.
|
|
Healthy Controls
Functional exercise capacity (6 minutes walk test), upper extremity exercise capacity (6 minutes Pegboard and Ring Test), respiratory functions (spirometer), respiratory muscle strength (mouth pressure measurement), peripheral muscle strength (dynamometer), respiratory muscle endurance (incremental threshold loading test), physical activity level (multi-sensor activity monitor), quality of life (European Cancer Research and Treatment Organization Quality of Life Scale (EORTC QOL C-30)), fatigue (Fatigue Severity Scale) and shortness of breath (Modified Medical Research Council (MMRC)) will be evaluated.
|
- Functional Exercise Capacity [ Time Frame: First Day ]Functional exercise capacity will be evaluated with 6-minute walking test according to the American Thoracic Society and European Respiratory Society criteria.
- Upper Extremity Exercise Capacity [ Time Frame: First Day ]The functional capacity of the upper extremities will be evaluated with a six-minute pegboard and ring test (6-PBRT). Subjects are asked to move as many rings as possible in 6 minutes. The score is the number of rings moved during the 6-minute period.
- Pulmonary function (Forced vital capacity (FVC)) [ Time Frame: First Day ]Pulmonary function will be evaluated with the spirometry. Dynamic lung volume measurements will be made according to American Thoracic Society and European Respiratory Society criteria. With the device, forced vital capacity (FVC) will be evaluated.
- Pulmonary function (Forced expiratory volume in the first second (FEV1)) [ Time Frame: First Day ]Pulmonary function will be evaluated with the spirometry. Dynamic lung volume measurements will be made according to American Thoracic Society and European Respiratory Society criteria. With the device, forced expiratory volume in the first second (FEV1) will be evaluated.
- Pulmonary function (FEV1 / FVC) [ Time Frame: First Day ]Pulmonary function will be evaluated with the spirometry. Dynamic lung volume measurements will be made according to American Thoracic Society and European Respiratory Society criteria. With the device, FEV1 / FVC will be evaluated.
- Pulmonary function (Flow rate 25-75% of forced expiratory volume (FEF 25-75%)) [ Time Frame: First Day ]Pulmonary function will be evaluated with the spirometry. Dynamic lung volume measurements will be made according to American Thoracic Society and European Respiratory Society criteria. With the device, flow rate 25-75% of forced expiratory volume (FEF 25-75%) will be evaluated.
- Pulmonary function (Peak flow rate (PEF)) [ Time Frame: First Day ]Pulmonary function will be evaluated with the spirometry. Dynamic lung volume measurements will be made according to American Thoracic Society and European Respiratory Society criteria. With the device, peak flow rate (PEF) will be evaluated.
- Respiratory Muscle Strength [ Time Frame: First Day ]Maximal inspiratory and expiratory muscle strength will be evaluated using mouth pressure device.
- Peripheral Muscle Strength [ Time Frame: Second Day ]Shoulder abduction and knee extensor muscle strength using portable hand held dynamometer will be evaluated.
- Respiratory Muscle Endurance [ Time Frame: First Day ]
Respiratory muscle endurance will be assessed by the POWERbreathe Wellness (POWERbreathe, Inspiratory Muscle Training (IMT) Technologies Ltd., Birmingham, UK) device and the respiratory muscle endurance test at increased threshold load.
The test will be started with 30% of the maximal inspiratory pressure and the pressure will be increased to 40%, 50%, 60%, %70, 80% 90% and 100% every two minutes. Patients will be asked to continue breathing through the device during the test. During the test, the number of breaths delivered during each 2-minute period will be recorded. If the individual cannot breathe 3 consecutive times, the test will be terminated by the physiotherapist.
The total duration of the test and the maximum pressure value at which it continues to breathe for at least 1 minute will be multiplied. The value found will be recorded as the respiratory muscle endurance value.
- Physical Activity Level [ Time Frame: Second Day ]Physical activity will be evaluated using multi sensor activity monitor.
- Disease Specific Quality of Life [ Time Frame: Second Day ]
Quality of life will be measured using Turkish version of European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 version 3.0 (EORTCQLQ).
The cancer-specific questionnaire has 30 questions and incorporates five functional scales, three symptom scales, a global health status and several single items. All item scores are transformed to 0-100. Higher values indicate higher functional/health level in functional scales, a higher quality of life level in global health status and increased symptoms in symptom scales.
- Fatigue [ Time Frame: Second Day ]Fatigue will be evaluated using Turkish version of Fatigue Severity Scale. This questionnaire includes 9 items and score range for each item from 1 to 7 point (7-point Likert scale). Fatigue Severity Scale score is calculates by deriving an arithmetic mean. Cut-scores of over 4 are indicative of significant fatigue (higher scores show more severe fatigue).
- Shortness of breath [ Time Frame: First Day ]
The Modified Medical Research Council (MMRC) dyspnea scale will be used to determine the perception of dyspnea during activities of daily living.
Dyspnea is graded as: zero (shortness of breath with strenuous exercise only); one (shortness of breath when rushing or walking up a slight uphill); two (because of shortness of breath they walk slower than people of the same age or have to stop to breathe while walking at their own pace); three (stops to breathe after walking 100 meters or after a few minutes); and four (too short of breath to leave the house or shortness of breath when getting dressed).
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 20 Years to 80 Years (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | Yes |
| Sampling Method: | Non-Probability Sample |
Inclusion criteria for patients group: Patients who are;
- pneumonectomy for lung cancer
- at least 6 weeks and at most 5 years after surgery
- being between ages of 20 and 80
- one of video-assisted thoracoscopic surgery or open thoracic surgery
Exclusion criteria for patients group: Patients who are;
- having comorbidities such as uncontrolled hypertension, diabetes mellitus, heart failure or atrial fibrillation
- having health problems such as cooperation
- having acute infection during evaluation
- having orthopedic, neurological, psychological, etc. problems that limit evaluations
Inclusion criteria for healthy group: Participants who are;
- willing to participate to the study
- being between ages of 20 and 80
Exclusion criteria for healthy group: Participants who are;
- having any diagnosis of chronic diseases
- having health problems such as cooperation
- having acute infection during evaluation
- being current smokers
- being ex-smokers (≥10 pack*years)
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04807153
| Contact: Meral BOŞNAK GÜÇLÜ, Prof.Dr. | 0312 216 2647 | meralbosnak@gazi.edu.tr | |
| Contact: Gülsüm SERTTAŞ, Pt | 0312 216 2647 | glsmserttas1@gmail.com |
| Turkey | |
| Gazi University Faculty of Health Sciences Department of Physiotherapy and Rehabilitation, Cardiopulmonary Rehabilitation Unit | Recruiting |
| Ankara, Çankaya, Turkey, 06490 | |
| Contact: Meral BOŞNAK GÜÇLÜ, Prof 0312 216 2647 meralbosnak@gazi.edu.tr | |
| Contact: Gülsüm SERTTAŞ, Pt 0312 216 2647 glsmserttas1@gmail.com | |
| Study Director: | Meral BOŞNAK GÜÇLÜ, Prof.Dr. | Gazi University | |
| Study Chair: | Gülsüm SERTTAŞ | Gazi University | |
| Principal Investigator: | Nur Dilvin ÖZKAN, MD | Gazi University | |
| Principal Investigator: | Ali ÇELİK, Assoc. Prof. | Gazi University | |
| Principal Investigator: | İsmail Cüneyt KURUL, Prof.Dr. | Gazi University |
| Responsible Party: | Meral Boşnak Güçlü, Prof. Dr., Gazi University |
| ClinicalTrials.gov Identifier: | NCT04807153 |
| Other Study ID Numbers: |
Gazi University 23 |
| First Posted: | March 19, 2021 Key Record Dates |
| Last Update Posted: | March 30, 2021 |
| Last Verified: | March 2021 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | No |
| Studies a U.S. FDA-regulated Drug Product: | No |
| Studies a U.S. FDA-regulated Device Product: | No |
|
Lung Cancer Pneumonectomy Exercise Capacity |
Upper Extremity Exercise Capacity Physical Activity Pulmonary Function |
|
Lung Neoplasms Respiratory Tract Neoplasms Thoracic Neoplasms Neoplasms by Site |
Neoplasms Lung Diseases Respiratory Tract Diseases |

